Merck KGaA Shares Rise After HSBC Upgrade to 'Buy'

Shares of Merck KGaA, the German science and technology group, gained 1.7% to reach €141.30 in recent trading after analysts at HSBC upgraded the stock to 'Buy' from 'Hold'. The bank cited a compelling combination of strong fundamentals and an attractive valuation as the basis for the re-rating.

The Upgrade Catalyst

In a note to clients, HSBC outlined three primary reasons for its more optimistic stance. Analysts pointed to the stock's failure to participate in a recent sector-wide rally, arguing the resulting valuation gap was unwarranted given the company's operational strength.

HSBC also highlighted Merck KGaA's robust growth during the first half of 2026. The bank named the company one of its preferred picks in the life sciences tools space, alongside industry peers Lonza, Danaher, and Agilent.

Strong Fundamentals

The upgrade is underpinned by the company's recent financial performance. According to its second-quarter 2026 results, Merck KGaA's organic sales growth accelerated to 4.1%, a notable increase from 2.9% in the first quarter.

Ad

Growth was driven by strong performance in its Life Science and Electronics divisions. The Life Science Process Solutions unit was a standout, expanding by 15% organically. Following the strong results, the company raised its full-year 2026 guidance, reinforcing the positive outlook articulated by HSBC.

Market Context

The stock's advance came in defiance of a weaker broader market, with major U.S. indices like the S&P 500 and Nasdaq trading lower. This suggests the rally was a stock-specific reaction to the analyst upgrade rather than a reflection of general market sentiment.

Even with the day's gains, Merck KGaA's stock trades below its 52-week high of €148.80, a factor that appears to support HSBC's view of an attractive entry point for investors.